NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws.

.

Investors have until July 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities.   The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Hauser v. Organon & Co., et al., No. 25-cv-05322.

Organon is a global healthcare company focused on women’s health that has historically rewarded its shareholders with a healthy dividend. In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company focused on dermatological conditions. As alleged, while the acquisition increased Organon’s debt, the Company assured investors it would maintain its dividend, which Organon asserted was its “#1 capital allocation priority.”

In truth, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt, ultimately leading the Company to severely cut its dividend.

On May 1, 2025, Organon announced that management reset the Company’s dividend payout from $0.28 per share to $0.02 per share. Organon’s CEO explained that the Company “reset our capital allocation priorities to accelerate progress towards deleveraging” and that “[b]y deleveraging more rapidly, we will continue to strengthen the future prospects of the company.” Organon’s CFO added, “[t]he biggest issues we face . . . relate to managing our leverage and relate to growth. And we need capital to solve both of those issues, and so returning capital to shareholders is right now, less of a priority.”

On this news, the price of Organon stock declined roughly 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025.

If you invested in Organon you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Or contact:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/organon-co-class-action

Attorney advertising. Past results do not guarantee future outcomes.